Form 4: Dianthus CFO Sells Shares After Option Exercise

Dianthus Therapeutics CFO Ryan Savitz exercised stock options and immediately sold 20,000 shares for a significant gain, as part of a pre-arranged trading plan.

Summary

• Ryan Savitz, the Chief Financial Officer and Chief Business Officer of Dianthus Therapeutics, Inc., executed a transaction involving the company's common stock.
• On September 9, 2025, Mr. Savitz exercised stock options to acquire 20,000 shares of common stock at an exercise price of $8.44 per share.
• Immediately following the exercise on the same date, Mr. Savitz sold all 20,000 acquired shares of common stock at a price of $35.00 per share.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Savitz on March 31, 2025.
• After these transactions, Mr. Savitz's direct beneficial ownership of common stock is 0 shares, while he retains 104,766 derivative securities (stock options).
• The underlying stock option award vested 25% on June 2, 2023, with the remaining three-quarters vesting in equal monthly installments over the subsequent three years, contingent on continued service.

Sentiment

Score: 7

Explanation: The sentiment is slightly positive. While insider selling can sometimes be viewed negatively, the significant profit realized by the CFO from the option exercise highlights the stock's appreciation. The transaction being under a Rule 10b5-1 plan also mitigates concerns about opportunistic selling.

Positives

• The CFO realized a substantial gain from the option exercise and sale, indicating significant appreciation in the company's stock price since the options were granted.
• The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, which suggests a planned, non-discretionary sale rather than one based on new, undisclosed information.

Negatives

• Insider selling, even under a 10b5-1 plan, reduces the direct equity exposure of a key executive, which some investors might view with caution.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The option exercises and sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 31, 2025.

Industry Context

Insider transactions, particularly those involving option exercises and sales under Rule 10b5-1 plans, are a common occurrence for executives in publicly traded companies across all industries, including biotechnology. They often represent a planned liquidity event or diversification strategy.

Corporate Governance

Stakeholder Impact

• Shareholders: May view the CFO's significant profit as a positive indicator of the company's stock performance. The 10b5-1 plan provides transparency regarding the transaction's pre-planned nature.
• Employees: No direct impact mentioned, but executive compensation practices are often observed.

Key Dates

Keywords

Dianthus Therapeutics, DNTH, Ryan Savitz, CFO, Insider Trading, Form 4, Stock Options, Rule 10b5-1 Plan, Equity Sales, Biotechnology